Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBVision Phase 2 Study of Tabelecleucel (Ebvallo) in EBV-associated Diseases
2024-516623-14-00Phase 2Authorised
- Sponsor
- Pierre Fabre Laboratories
- Start
- Oct 2024
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of tabelecleucel in EBV-positive lymphoproliferative disorder (EBV-LPD), Post-Transplant Lymphoproliferative Disorder (PTLD), Bone and soft tissue sarcoma and 2 more, sponsored by Pierre Fabre Laboratories. Primary endpoint: Overall response rate (ORR). Planned start Oct 2024; status: authorised.
02
Drugs
tabelecleucel
03
Conditions
EBV-positive lymphoproliferative disorder (EBV-LPD)Post-Transplant Lymphoproliferative Disorder (PTLD)Bone and soft tissue sarcomaleiomyosarcoma (LMS)Smooth muscle neoplasm
Beyond the preview
Go deeper on 2024-516623-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516623-14-00.